Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-705

@kervio Good post mate. I’m sure Silvio wouldn’t have plucked the initial guidance out of thin air, the NIH would have given Silvio the guidance in April. And as you alluded to, the upswing in the pandemic has on balance likely complicated and hindered recruitment rather than been of assistance even though there’s no shortage of unfortunate candidates. I do think though that some colour on this slippage of timelines should have been given at AGM or earlier.

@RickyH Nothing but unsubstantiated and emotional diatribe from you speculating and wildly trying to justify the delays but with no facts to back any of that up.

@Lopez You said MSB are full steam ahead leaving shade throwers like me in their wake. I’m a shareholder and hopeful and positive about the very near term prospects just like you. Asking a justifiable question of management doesn’t make me a ‘shade thrower’ as you put it but I have never been a blinkered pom pom waving cheerleader of any stock like many on these forums.

Have a great day.